Literature DB >> 9671926

Immunohistochemical detection of activin A, follistatin, and activin receptors during fracture healing in the rat.

T Nagamine1, T Imamura, Y Ishidou, M Kato, F Murata, P ten Dijke, T Sakou.   

Abstract

Activins are multifunctional proteins that belong to the transforming growth factor-beta superfamily and are thought to play an important role in modulating the formation of bone. Activins exert their cellular effects by way of activin type-I and type-II serine/threonine kinase receptors. Follistatin is an activin-binding protein that can suppress the biological effects of activins. In this study, the immunohistochemical expression of activin A, follistatin, and activin receptors was studied during fracture healing in the rat. Activin A was weakly detected in the periosteum near the fracture ends at an early stage but was absent in the chondrocytes around the fracture gap, where endochondral ossification took place. An antibody to follistatin stained osteogenic cells in the periosteum near the fracture ends; moderate and strong staining were observed in proliferating, mature, and hypertrophied chondrocytes at the sites of endochondral ossification. Levels of activin A and follistatin were high near the osteoblasts on the surface of the newly formed trabecular bone. In addition, an intense localization of activin A was noted where multinucleated osteoclast-like cells were present. This study suggests that the activin-follistatin system may contribute to cellular events related to the formation and remodeling of bone during fracture healing. Activin type-I and type-II receptors were co-expressed in intramembranous and endochondral ossification sites. The expression of activin type-I, type-II, and type-IIB receptors in the absence of activin A in the endochondral ossification suggests that other isoforms of activins may signal by way of these receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671926     DOI: 10.1002/jor.1100160307

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  7 in total

1.  Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury.

Authors:  Mark W Hamrick; Phonepasong Arounleut; Ethan Kellum; Matthew Cain; David Immel; Li-Fang Liang
Journal:  J Trauma       Date:  2010-09

2.  Myostatin (GDF-8) inhibits chondrogenesis and chondrocyte proliferation in vitro by suppressing Sox-9 expression.

Authors:  Moataz Elkasrawy; Sadanand Fulzele; Matthew Bowser; Karl Wenger; Mark Hamrick
Journal:  Growth Factors       Date:  2011-07-15       Impact factor: 2.511

3.  Immunolocalization of myostatin (GDF-8) following musculoskeletal injury and the effects of exogenous myostatin on muscle and bone healing.

Authors:  Moataz Elkasrawy; David Immel; Xuejun Wen; Xiaoyan Liu; Li-Fang Liang; Mark W Hamrick
Journal:  J Histochem Cytochem       Date:  2012-01       Impact factor: 2.479

4.  Overexpression of Smad7 results in severe pathological alterations in multiple epithelial tissues.

Authors:  Wei He; Allen G Li; Dongyan Wang; Shuhua Han; Biao Zheng; Marie-José Goumans; Peter Ten Dijke; Xiao-Jing Wang
Journal:  EMBO J       Date:  2002-06-03       Impact factor: 11.598

Review 5.  Myostatin (GDF-8) as a key factor linking muscle mass and bone structure.

Authors:  M N Elkasrawy; M W Hamrick
Journal:  J Musculoskelet Neuronal Interact       Date:  2010-03       Impact factor: 2.041

6.  Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume.

Authors:  Ethan Kellum; Harlan Starr; Phonepasong Arounleut; David Immel; Sadanand Fulzele; Karl Wenger; Mark W Hamrick
Journal:  Bone       Date:  2008-09-13       Impact factor: 4.398

7.  Soluble activin type IIB receptor improves fracture healing in a closed tibial fracture mouse model.

Authors:  Tero Puolakkainen; Petri Rummukainen; Jemina Lehto; Olli Ritvos; Ari Hiltunen; Anna-Marja Säämänen; Riku Kiviranta
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.